Emerging Circulating MiRNAs and LncRNAs in Upper Gastrointestinal Cancers.

Emerging Circulating MiRNAs and LncRNAs in Upper Gastrointestinal Cancers. Expert Rev Mol Diagn. 2020 Oct 24;: Authors: Abdi E, Latifi-Navid S, Abdi F, Taherian-Esfahani Z Abstract INTRODUCTION: Circulating non-coding RNAs (ncRNAs) possess high stability in circulation, making them capable of being utilized in the diagnosis, prognosis, and treatment of upper gastrointestinal (GI) tract cancers as non-invasive biomarkers. Areas covered: Herein, the potential clinical application of emerging circulating miRNAs and lncRNAs in upper GI cancers are comprehensively reviewed. In the end, innovative approaches on therapeutic strategies targeting ncRNAs and their delivery systems are discussed. Expert opinion: For esophageal cancer (EC), the circulating miRNAs, miR-21, miR-223, and miR-375 have been validated as promising diagnostic biomarkers in a meta-analysis. For gastric cancer (GC), miR-17, miR-18a, miR-21, miR-25, miR-223, miR-451, and lncRNA-H19 have been reported in several studies and are likely to be promising biomarkers. Unlike EC, many circulating lncRNAs have been newly reported for GC and each is often limited to one study. They often show excellent or outstanding discrimination performance, such as XIST, LOC100506474, UCA1, LINC00467, ZNFX1-AS1, HULC, AA174084, CEBPA-AS1, MIAT, PCSK2-2:1, HOTTIP, H19 (AUCs 0.8 to 0.9), and particularly CUDR, LSINCT-5, PTENP1, HOTAIR, and LncRNA-GC1 (AUCs > 0.9). Most importantly, using a gro...
Source: Expert Review of Molecular Diagnostics - Category: Laboratory Medicine Tags: Expert Rev Mol Diagn Source Type: research